BR112012030261A2 - nova composição farmacêutica sinergística para a preparação de formulações tópicas para a pofilaxia e tratamento de feridas, feridas por queimaduras, exertos de pele, úlceras de pressão e úlceras do pé diabético - Google Patents

nova composição farmacêutica sinergística para a preparação de formulações tópicas para a pofilaxia e tratamento de feridas, feridas por queimaduras, exertos de pele, úlceras de pressão e úlceras do pé diabético

Info

Publication number
BR112012030261A2
BR112012030261A2 BR112012030261A BR112012030261A BR112012030261A2 BR 112012030261 A2 BR112012030261 A2 BR 112012030261A2 BR 112012030261 A BR112012030261 A BR 112012030261A BR 112012030261 A BR112012030261 A BR 112012030261A BR 112012030261 A2 BR112012030261 A2 BR 112012030261A2
Authority
BR
Brazil
Prior art keywords
wounds
ulcers
pofilaxia
excerpts
skin
Prior art date
Application number
BR112012030261A
Other languages
English (en)
Other versions
BR112012030261B1 (pt
Inventor
Sharma Khajesh
Mohan Vadrevu Krishna
Cherish Babu Pelluri Venkata
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of BR112012030261A2 publication Critical patent/BR112012030261A2/pt
Publication of BR112012030261B1 publication Critical patent/BR112012030261B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012030261A 2010-06-03 2010-07-14 formulação farmacêutica tópica BR112012030261B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1534CH2010 2010-06-03
PCT/IN2010/000468 WO2011151835A1 (en) 2010-06-03 2010-07-14 A novel synergistic pharmaceutical composition for topical applications

Publications (2)

Publication Number Publication Date
BR112012030261A2 true BR112012030261A2 (pt) 2017-10-31
BR112012030261B1 BR112012030261B1 (pt) 2019-12-03

Family

ID=43466804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030261A BR112012030261B1 (pt) 2010-06-03 2010-07-14 formulação farmacêutica tópica

Country Status (12)

Country Link
US (1) US9427459B2 (pt)
EP (1) EP2575861B1 (pt)
JP (1) JP5824513B2 (pt)
KR (1) KR101457509B1 (pt)
CN (1) CN102939097B (pt)
AU (1) AU2010354681C1 (pt)
BR (1) BR112012030261B1 (pt)
CA (1) CA2800417C (pt)
CO (1) CO6650416A2 (pt)
MX (1) MX338611B (pt)
RU (1) RU2571506C2 (pt)
WO (1) WO2011151835A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687429B2 (en) 2007-06-20 2017-06-27 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing low concentrations of botanicals
EP2166840B1 (en) 2007-06-20 2017-01-11 The Trustees of Columbia University in the City of New York Bio-film resistant surfaces
US9511040B2 (en) 2007-06-20 2016-12-06 The Trustees Of Columbia University In The City Of New York Skin and surface disinfectant compositions containing botanicals
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
WO2013067150A2 (en) 2011-11-03 2013-05-10 The Trustees Of Columbia University In The City Of New York Composition with sustained antimicrobial activity
US9968101B2 (en) 2011-11-03 2018-05-15 The Trustees Of Columbia University In The City Of New York Botanical antimicrobial compositions
TW201330856A (zh) 2011-12-06 2013-08-01 Univ Columbia 廣效性的天然防腐組成物
CN103182070B (zh) * 2013-04-12 2014-02-12 江苏迪沃生物制品有限公司 一种外用组合物、制剂及其应用
CN103784463B (zh) * 2014-01-28 2015-04-22 滨州医学院附属医院 一种新复方磺胺嘧啶银混悬剂及其制备方法
EP3340792A1 (en) 2015-08-24 2018-07-04 Smith & Nephew, Inc Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms
WO2017045060A1 (en) * 2015-09-15 2017-03-23 The Governors Of The University Of Alberta Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria
CN105251011B (zh) * 2015-11-13 2018-12-28 广州骏思知识产权管理咨询有限公司韶关分公司 一种用于浅度烧伤的喷膜剂及其制备方法
CN105214093B (zh) * 2015-11-16 2016-10-26 马文学 一种复方微胶愈伤护理液
CN110167516B (zh) 2017-01-31 2022-08-30 金伯利-克拉克环球有限公司 包含苯甲酸酯的抗细菌组合物及利用该组合物抑制细菌生长的方法
CN107625725B (zh) * 2017-09-08 2021-11-16 中国科学院过程工程研究所 基于氨基酸的含纳米银的抗菌水凝胶及其制备方法和用途
CN111518288B (zh) * 2020-05-13 2022-06-24 福州大学 一种复合水凝胶伤口敷料及其制备方法
CN113813283B (zh) * 2020-06-19 2023-12-12 中山大学附属第六医院 一类化合物促皮肤损伤修复的用途
CN113599506B (zh) * 2021-05-31 2023-07-21 长沙理工大学 一种铂纳米酶/葡萄糖氧化酶@透明质酸复合抗菌材料及其制备和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563461B2 (en) * 2002-02-07 2009-07-21 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
AU2003303783A1 (en) 2003-01-16 2004-08-13 Xylos Corporation Microbial-derived cellulose amorphous hydrogel wound dressing
CN101217938A (zh) * 2005-05-27 2008-07-09 博哈拉特生物技术国际有限公司 表皮生长因子组合物，其方法及其应用

Also Published As

Publication number Publication date
AU2010354681B2 (en) 2014-08-28
US9427459B2 (en) 2016-08-30
CA2800417C (en) 2018-08-28
EP2575861A1 (en) 2013-04-10
KR101457509B1 (ko) 2014-11-05
CN102939097A (zh) 2013-02-20
RU2571506C2 (ru) 2015-12-20
CO6650416A2 (es) 2013-04-15
EP2575861B1 (en) 2015-11-04
CA2800417A1 (en) 2011-12-08
AU2010354681A1 (en) 2012-12-20
WO2011151835A1 (en) 2011-12-08
KR20130043145A (ko) 2013-04-29
JP5824513B2 (ja) 2015-11-25
AU2010354681C1 (en) 2015-02-05
US20130085103A1 (en) 2013-04-04
CN102939097B (zh) 2016-05-11
BR112012030261B1 (pt) 2019-12-03
RU2012156266A (ru) 2014-07-20
MX338611B (es) 2016-04-25
JP2013527229A (ja) 2013-06-27
MX2012014051A (es) 2013-02-15

Similar Documents

Publication Publication Date Title
BR112012030261A2 (pt) nova composição farmacêutica sinergística para a preparação de formulações tópicas para a pofilaxia e tratamento de feridas, feridas por queimaduras, exertos de pele, úlceras de pressão e úlceras do pé diabético
SV2010003674A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112012027707A2 (pt) dispositivo médico para tratar tecido rígido
BRPI0906527A2 (pt) aparelho para aplicação de bandagens em ferimentos e bandagem médica
BR112012029746A2 (pt) composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
IL231509A0 (en) Tissue wound healing products
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013014583A2 (pt) composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
IL251543B (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
EP2564873A4 (en) MEANS FOR THE SUPPRESSION OF SKIN IRRITATIONS AND TRANSDERMAL PREPARATION THEREOF
BRPI0913983A2 (pt) composição cosmética e/ou terapêutica, e, método para fabricar um produto para cuidado da pele tópico
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
BRPI1006024B8 (pt) composição cosmética emulsificada para cuidado da pele
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
BR112012024630B8 (pt) Processos para o tratamento cosmético de envelhecimento da pele
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
WO2011125070A3 (en) Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/07/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/07/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.